---
title: "Eyepoint Pharmaceuticals Announces Phase 3 Program Initiation For Duravy In Diabetic Macular Edema"
description: "Oct 14 (Reuters) - EyePoint Pharmaceuticals Inc:* EYEPOINT PHARMACEUTICALS INC - ANNOUNCES PHASE 3 PROGRAM INITIATION FOR DURAVY IN DIABETIC MACULAR EDEMA Source text: Further company coverage:"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261129466.md"
published_at: "2025-10-14T20:21:40.000Z"
---

# Eyepoint Pharmaceuticals Announces Phase 3 Program Initiation For Duravy In Diabetic Macular Edema

> Oct 14 (Reuters) - EyePoint Pharmaceuticals Inc:* EYEPOINT PHARMACEUTICALS INC - ANNOUNCES PHASE 3 PROGRAM INITIATION FOR DURAVY IN DIABETIC MACULAR EDEMA Source text: Further company coverage:

Oct 14 (Reuters) - EyePoint Pharmaceuticals Inc (EYPT.O) : \* EYEPOINT PHARMACEUTICALS INC - ANNOUNCES PHASE 3 PROGRAM INITIATION FOR DURAVY IN DIABETIC MACULAR EDEMA Source text: Further company coverage: (EYPT.O)

### Related Stocks

- [EYPT.US - EyePoint](https://longbridge.com/en/quote/EYPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program | EyePoint Pharmaceuticals (NASDAQ:EYPT) presented at the Guggenheim Emerging Biotech Summit 2026, discussing its lead ret | [Link](https://longbridge.com/en/news/275950536.md) |
| EyePoint Inc. to Present at Guggenheim Emerging Outlook Biotech Summit | EyePoint Inc. will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12 | [Link](https://longbridge.com/en/news/274967127.md) |
| EyePoint Inc. Chief Medical Officer Ramiro Ribeiro Reports Disposal of Common Shares | Ramiro Ribeiro, Chief Medical Officer of EyePoint Inc., has reported the disposal of common shares of the company. The f | [Link](https://longbridge.com/en/news/271837277.md) |
| EyePoint Pharmaceuticals (EYPT) Valuation Check After DURAVYU Phase 3 And NDA Progress | EyePoint Pharmaceuticals (EYPT) is under scrutiny following updates on DURAVYU's Phase 3 trials and potential NDA filing | [Link](https://longbridge.com/en/news/272184213.md) |
| EyePoint Inc. to Present at J.P. Morgan Healthcare Conference | EyePoint Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, at | [Link](https://longbridge.com/en/news/271784400.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.